Rapport (NASDAQ: RAPP) insider lines up stock sale after August plan trades

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. (RAPP) has a notice under Rule 144 filed by officer Krishnaswamy Yeleswaram to sell 37,000 shares of common stock through Morgan Stanley Smith Barney LLC. The proposed sale references an aggregate market value of $1,825,210.00 and outstanding common shares of 47,978,286 on NASDAQ.

The shares to be sold were acquired upon the vesting of founders shares during the period from 06/09/2024 through 02/09/2025. In the past three months, separate 10b5-1 plan sales by the same person included 13,160 shares for $657,977.63 on 08/24/2026 and 404 shares for $20,159.60 on 08/19/2026.

Key Figures

Shares to be sold under Rule 144: 37,000 shares Aggregate market value of shares to be sold: $1,825,210.00 Common shares outstanding: 47,978,286 shares +4 more

7 metrics

Shares to be sold under Rule 144 37,000 shares Proposed sale of Rapport Therapeutics, Inc. common stock by officer Krishnaswamy Yeleswaram

Aggregate market value of shares to be sold $1,825,210.00 Value associated with 37,000 common shares in the Rule 144 notice

Common shares outstanding 47,978,286 shares Outstanding Rapport Therapeutics, Inc. common stock referenced in the notice

10b5-1 sale on 08/24/2026 13,160 shares for $657,977.63 Common stock sale for Krishnaswamy Yeleswaram reported in past 3 months

10b5-1 sale on 08/19/2026 404 shares for $20,159.60 Common stock sale for Krishnaswamy Yeleswaram reported in past 3 months

Vesting period for founders shares 06/09/2024 through 02/09/2025 Period during which the founders shares underlying the sale vested

Date of notice 08/25/2026 Date on which the Rule 144 notice was signed by Krishnaswamy Yeleswaram

Key Terms

Rule 144, founders shares, 10b5-1, Form 144

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

founders shares financial

"The securities to be sold were acquired upon the vesting of founders shares"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

10b5-1 regulatory

"10b5-1 Sales for KRISHNASWAMY 99 High Street, Suite 2100 Boston MA 02110"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

What insider transaction is disclosed for RAPP in this Form 144?

The filing reports that officer Krishnaswamy Yeleswaram has filed a Rule 144 notice to sell 37,000 shares of Rapport Therapeutics, Inc. common stock. The shares were acquired upon vesting of founders shares between 06/09/2024 and 02/09/2025.

What is the aggregate market value of the RAPP shares proposed to be sold?

The Rule 144 notice lists an aggregate market value of $1,825,210.00 for the 37,000 Rapport Therapeutics, Inc. common shares that are proposed to be sold through Morgan Stanley Smith Barney LLC.

How many Rapport Therapeutics (RAPP) shares are reported as outstanding?

The notice references 47,978,286 shares of Rapport Therapeutics, Inc. common stock as outstanding. This figure is provided as context for the Rule 144 sale and is separate from the 37,000 shares covered by the notice.

What prior 10b5-1 sales by the insider in RAPP are disclosed?

The filing lists 10b5-1 sales for Krishnaswamy Yeleswaram of 13,160 shares for $657,977.63 on 08/24/2026 and 404 shares for $20,159.60 on 08/19/2026, both involving common stock of Rapport Therapeutics, Inc.

How were the RAPP shares to be sold originally acquired by the insider?

The notice states that the securities to be sold were acquired upon the vesting of founders shares during the period from 06/09/2024 through 02/09/2025.

Which broker is handling the proposed RAPP share sale under Rule 144?

The proposed sale of 37,000 Rapport Therapeutics, Inc. common shares is listed as being through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 04:29 PM Accepted by SEC EDGAR 08/25/2026 - 04:29 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002022156
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Rapport Therapeutics, Inc.
SEC File Number	001-42121
Address of Issuer	99 High Street, Suite 2100 Boston MASSACHUSETTS 02110
Phone	8573218020
Name of Person for Whose Account the Securities are To Be Sold	KRISHNASWAMY YELESWARAM
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	37000	1825210.00	47978286	08/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/09/2024	Founders Shares	Issuer			37000	06/09/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for KRISHNASWAMY YELESWARAM 99 High Street, Suite 2100 Boston MA 02110	Common	08/24/2026	13160	657977.63
10b5-1 Sales for KRISHNASWAMY YELESWARAM 99 High Street, Suite 2100 Boston MA 02110	Common	08/19/2026	404	20159.60

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of founders shares during the period of 06/09/2024 through 2/9/2025
Date of Notice	08/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Krishnaswamy Yeleswaram
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)